AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.290
+0.020 (1.57%)
Apr 24, 2025, 4:00 PM EDT - Market closed
AN2 Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for AN2 Therapeutics stock have an average target of 3.50, with a low estimate of 2.00 and a high estimate of 5.00. The average target predicts an increase of 171.32% from the current stock price of 1.29.
Analyst Consensus: Buy
* Price targets were last updated on Mar 26, 2025.
Analyst Ratings
The average analyst rating for AN2 Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $5 | Buy | Reiterates | $5 | +287.60% | Mar 26, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $5 | Buy | Reiterates | $5 | +287.60% | Feb 25, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +287.60% | Feb 3, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +287.60% | Nov 19, 2024 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 18, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.08
from -1.72
EPS Next Year
-1.25
from -1.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | n/a | n/a | n/a | |
| Avg | n/a | n/a | n/a | |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.99 | -0.98 | -1.04 |
| Avg | -1.08 | -1.25 | -1.01 |
| Low | -1.25 | -1.59 | -0.97 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.